More Topics:
Biopharma co. Bind Biosciences Completes $4.8M Offering - cbl
Posted October 13, 2011
We Recommend...
Scott Minick
By Brian Wolak
CAMBRIDGE -- BIND Biosciences has completed a $4.75 million offering, taking in the amount from five investors and adding to a $12.42 million round completed last year.
Headquartered in Cambridge, BIND Biosciences engineers targeted therapeutics with initial product development efforts in the oncology, cardiovascular disorders, inflammatory disease and RNAi therapeutics areas.
CEO Scott Minick is named in an SEC filing disclosing the capital raise along with other executives and directors, including Noubar Afeyan from Flagship Ventures; Omid Farokhzad, founder and Harvard associate professor; Peter Barton Hutt, senior counsel at Covington & Burling; among others.
Prior joining BIND, Minick was a Managing Director of Arch Venture Partners, where he helped lead investments in BIND, XenoPort, MedVantx, Achaogen, Celula, and Sorbent Therapeutics.
In July, citybizlist reported that BIND Biosciences Inc. leased the last available space, 32,800 square feet, at BioMed Realty Trust Inc.'s Vassar Street property.
SEC filing: http://tinyurl.com/5uk4vch
To find out more about the company in this article and to see if you
have business connections, click below:
blog comments powered by